Loading...
Market
Which major pharmaceutical company will partner with Texas Biomed for CDO-7N-1 production by December 31, 2024?
3
Resolution / Starting Odds
Pfizer • 25%
Moderna • 25%
Johnson & Johnson • 25%
Other • 25%
Official announcements from Texas Biomed or the pharmaceutical companies
Story
Texas Biomed Discovers Antibody CDO-7N-1 Neutralizing All COVID-19 Variants
Sep 10, 2024, 12:27 PM
Researchers at Texas Biomed have discovered an antibody, CDO-7N-1, that can neutralize all known variants of SARS-CoV-2, the virus responsible for COVID-19. This antibody induces immunity to all major SARS-CoV-2 proteins and is highly effective against all major variants to date. Additionally, the antibody has shown effectiveness against distantly related SARS-like coronaviruses that infect other animals. This breakthrough could have significant implications for the treatment and prevention of COVID-19 and related viral infections.
View original story
Similar markets
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
Other • 25%
Yes • 50%
No • 50%
Pfizer • 25%
Moderna • 25%
Johnson & Johnson • 25%
Other • 25%
Pfizer • 25%
Roche • 25%
Merck • 25%
Other • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
Other • 25%
Yes • 50%
No • 50%
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
Other • 25%
Johnson & Johnson • 25%
Merck • 25%
AstraZeneca • 25%
Other • 25%
Yes • 50%
No • 50%
Pfizer • 25%
Roche • 25%
Johnson & Johnson • 25%
Novartis • 25%